The Rheumatology Podcast

Dr Steven Zhao asks Dr Lewis Carpenter (King’s College London, UK) about his recent paper, which found that improvements in early RA clinical markers were not translated into similar improvements in patient-reported outcomes. They highlight the necessity of holistic treatment to manage pain, fatigue and mental health, as well as the importance of multidisciplinary teams in clinical practice.

Dr Steven Zhao asks Dr Lewis Carpenter (King’s College London, UK) about his recent paper, which found that improvements in early RA clinical markers were not translated into similar improvements in patient-reported outcomes. They highlight the necessity of holistic treatment to manage pain, fatigue and mental health, as well as the importance of multidisciplinary teams in clinical practice.

Dr Chris Wincup asks Dr Md Yuzaiful Md Yusof (Leeds, UK) about his recent paper, which examines the effect of rituximab and TNF inhibitors on lung infection and survival in RA-associated bronchiectasis. They discuss the study’s aims, design and main findings, as well as key messages for clinicians.

Dr James Galloway asks Dr Philip Hamann (University of Bristol, UK) about his recent paper, which identifies disease activity trajectories in RA patients receiving their first anti-TNF. They discuss the paper’s key findings and the challenges of working with real world data, as well as Dr Hamann’s work as a Turing Fellow.

Dr James Galloway asks Dr Philip Hamann (University of Bristol, UK) about his recent paper, which identifies disease activity trajectories in RA patients receiving their first anti-TNF. They discuss the paper’s key findings and the challenges of working with real world data, as well as Dr Hamann’s work as a Turing Fellow.

Dr Mrinalini Dey asks Dr Kathrine Grøn (Copenhagen, Denmark) about her recent paper, which examines infection risk in RA patients treated with abatacept, rituximab and tocilizumab. They discuss the DANBIO cohort, the differences in incidence rates between biologic-naïve patients and switchers, and also consider the results in the context of COVID-19. This paper is the Editor’s Choice for August 2020."

Dr Mrinalini Dey asks Dr Kathrine Grøn (Copenhagen, Denmark) about her recent paper, which examines infection risk in RA patients treated with abatacept, rituximab and tocilizumab. They discuss the DANBIO cohort, the differences in incidence rates between biologic-naïve patients and switchers, and also consider the results in the context of COVID-19. This paper is the Editor’s Choice for August 2020."

Dr Mrinalini Dey asks Dr Kathrine Grøn (Copenhagen, Denmark) about her recent paper, which examines infection risk in RA patients treated with abatacept, rituximab and tocilizumab. They discuss the DANBIO cohort, the differences in incidence rates between biologic-naïve patients and switchers, and also consider the results in the context of COVID-19. This paper is the Editor’s Choice for August 2020."

Dr Mrinalini Dey asks Dr Kathrine Grøn (Copenhagen, Denmark) about her recent paper, which examines infection risk in RA patients treated with abatacept, rituximab and tocilizumab. They discuss the DANBIO cohort, the differences in incidence rates between biologic-naïve patients and switchers, and also consider the results in the context of COVID-19. This paper is the Editor’s Choice for August 2020."

Dr Marwan Bukhari talks to Dr Kanta Kumar (University of Birmingham, UK) about her recent Editorial, which highlights the impact of COVID-19 on ethnic minority groups. Dr Kumar and the team call for more patient engagement, as well as support from societies to commission large-scale research which could inform national and international policy.